Small cell intestinal lymphoma has not been well characterized in dogs. The objective of this study was to describe clinical characteristics and outcome in dogs with small cell intestinal lymphoma. We hypothesized that affected dogs would have prolonged survival compared with high-grade gastrointestinal (GI) lymphoma. Pathology records were searched for dogs with histologically confirmed small cell GI lymphoma. Seventeen dogs with confirmed small cell intestinal lymphoma were identified, and clinical and outcome data were retrospectively collected.
grade disease, [3] [4] [5] with few isolated cases of small cell GI lymphoma interspersed into these studies. Recently, the pathological findings associated with small cell GI lymphoma in dogs have been described, including the uncommon nature of the disease, however, limited clinical, treatment and outcome information was presented in these studies. [6] [7] [8] [9] [10] More recently, 20 dogs with low-grade GI lymphoma were described by Lane et al. A majority of dogs were treated with a combination of chlorambucil and prednisone, with a reported median survival time (MST) of 424 days. No factors were found to be associated with survival.
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In cats, it is well established that small cell (low-grade) GI lym- guidelines. [19] [20] [21] Classification for lymph node enlargement was binary (yes/no). Follow-up information was obtained by contact with referring veterinarians, clients, or both. To meet selection criteria, dogs required follow-up for at least 1 veterinary visit after diagnosis or until death.
All pathology samples were reviewed by a single board-certified pathologist (P.F.M.), and criteria for diagnosis of small cell lymphoma was based on the presence of a predominantly small lymphocytic infiltrate, IHC with CD3 antibody to confirm T-cell phenotype, and molecular clonality assessment with polymerase chain reaction (PCR) as described previously. 18, 22 T-cell phenotype was established when the dominant lymphoid population in the lamina propria and epithelium were CD3 positive. B-cell IHC and clonality was planned in dogs that were not CD3 positive on IHC.
The Kaplan-Meier product limit method was used to estimate survival, which was defined as the date biopsies were obtained to the date of death from any cause, and the log-rank test was used to assess the effect of various factors on survival. Survival times were censored if dogs were alive at the study's end or lost to follow-up.
Death was assumed to be related to lymphoma in all cases. Factors assessed for effect on survival include presenting complaints of diarrhoea, vomiting, weight loss and presence of a low BCS (defined as <5 on a 9-point scale, with 5 being the ideal BCS 23 ), anaemia, hypocobalaminemia, hypoalbuminemia, effusion at the time of diagnosis and treatment received. A P-value of <.05 was considered statistically significant.
| RESULTS
Seventeen dogs with small cell intestinal lymphoma met selection criteria. Two (12%) dogs underwent full-thickness biopsies during an abdominal exploratory procedure and 15 (88%) had partial-thickness biopsies obtained endoscopically.
Patient characteristics, owner reported presenting complaints and physical examination findings are listed in Table 1 . The median age was 9 (range 2-13 years) and the median body weight was A complete blood count (CBC) from the time of diagnosis was available for 14 (82%) dogs. There were no abnormal findings on CBC in 6 (43%) dogs. The abnormal CBC findings are reported in Table 2 .
A biochemical panel from the time of diagnosis was available for 16 of 17 (94%) dogs. All evaluable dogs had at least 1 abnormal finding. The main biochemical abnormalities are reported in abnormal wall layering (n = 7, 54%), hyperechoic mucosal striations (n = 7, 54%), enlarged abdominal lymph nodes (n = 6, 46%), fluid contents within the lumen (n = 6, 46%), thickened muscularis propria (n = 5, 38%) and effusion (n = 5, 38%). Effusion was sampled in 3 of 5 dogs (60%), and was consistent with a transudate in all sampled.
Abnormalities were present in all sections of the small intestinal tract in 3 (23%) dogs, and only within the duodenum and jejunum in 5 (38%) dogs. In dogs with enlarged abdominal lymph nodes, the median measurement was 0.6 cm (range 0.579-1.08 cm).
All dogs were confirmed to have small cell intestinal lymphoma on pathology review. The most salient features on routine HE were predominantly lymphocytic infiltrates within the intestinal villous lamina propria and epithelium. These infiltrates were often more pronounced in the villous tips. All lymphomas in the current study were Dull heart and lung sounds 1 6
Painful abdomen 1 6 Dehydration 1 6 confirmed disease in abdominal lymph nodes. There were no dogs with confirmed small cell lymphoma in the stomach or the colon.
While 88% of dogs underwent endoscopy for biopsy procurement, 65% of dogs (n = 11) had ileal samples obtained for histopathology.
Overall, 14 (82%) dogs underwent some form of therapy. Six Additionally, the MST in the current study is more favourable compared with historic reports of dogs with high-grade GI lymphoma, suggesting that it is, in fact, a separate disease entity. [3] [4] [5] Three factors in the current study were shown to significantly influence survival, including weight loss or anaemia at the time of diagnosis which were present in 41% and 36% of dogs, respectively, and the type of therapy received. Weight loss and anaemia at the time of diagnosis have not been previously reported as prognostic factors in cats with small cell GI lymphoma or in dogs with high-grade GI lymphoma, however, both a low BCS at diagnosis and anaemia have been reported as overall negative prognostic indicators in dogs with lymphoma. 24, 25 Dogs that were underweight at the time of diagnosis of lymphoma were reported to have a lower MST in Romano's study compared with dogs that had an ideal weight or were overweight. 25 The presence of anaemia at diagnosis has been correlated with a decreased survival in dogs with lymphoma, conferring a 2.37-fold higher likelihood of death in dogs with a packed cell volume < 35%. 24 Within the current study population, there are many possible explanations for the anaemia present in 5 dogs, including anaemia of inflammatory disease, iron deficiency anaemia related to chronic GI haemorrhage, or production of anaemia-inducing substance by tumour cells. [26] [27] [28] The presence of weight loss at the time of diagnosis may be indicative of more severe infiltration of disease leading to malabsorption in those dogs, which may account for their worsened survival. Additionally, weight loss may contribute to concern for a worsened quality of life which may more readily prompt humane euthanasia. In the current study, there were 3 dogs that did not undergo any form of therapy which affected the overall MST reported (279 days), and was also significantly associated with a lower MST (P = .002). The lack of treatment in these 3 dogs could have been, in part, because of a decreased awareness of this disease entity, resulting in a guarded prognosis being given to the owners based on previous reports of poor outcomes in dogs with high-grade GI lymphoma. in previous studies. [6] [7] [8] [9] [10] [11] There were various hematologic and biochemical abnormalities found within the dogs in the current study, most of which can be explained by presence of infiltrative GI disease.
Hypoalbuminemia was present in 69% of the dogs in the current study and has been reported in up to 49% of cats with small cell GI lymphoma 29 although was not present in any cats within a separate study. 17 Hypoalbuminemia was also reported in 50% of dogs in the recent Lane et al study. 11 It is likely that the hypoalbuminemia present in dogs within the current study occurred primarily because of loss of low molecular weight proteins across a compromised intestinal wall. 29 In the current study, hypoalbuminemia showed no statistical influence on survival, however, further studies will be beneficial to help confirm this. Hypocobalaminemia was present in 71% of dogs evaluated in the current study, which is similar to the proportion of cats with small cell GI lymphoma (78%) presenting with hypocobalaminemia 16 and higher than Lane et al's recent report of dogs with low-grade GI lymphoma. 11 Cobalamin is absorbed exclusively in the ileum, as a complex of intrinsic factor and cobalamin, and is a cofactor in several important enzymatic reactions. 30 Given the high percentage of hypocobalaminemic dogs in the current study, it would be useful to routinely measure this value in dogs with small cell intestinal lymphoma in order to understand the clinical implications and to initiate parenteral supplementation if necessary. This value could also be monitored throughout a treatment protocol, to ensure no changes in supplementation are necessary.
The reported ultrasonographic features of small cell intestinal lymphoma in cats include diffuse intestinal wall thickening (most specifically, a thickened muscularis propria) with or without preservation of wall layering and mesenteric lymph node enlargement. 17, 31 In the current study, these were also common findings in dogs. Two additional findings that have not been as commonly reported in cats with small cell intestinal lymphoma include hyperechoic mucosal striations and effusion, both of which are seen commonly in dogs with protein losing enteropathies, most specifically intestinal lymphangiectasia. 32 It is proposed that the hyperechoic mucosal striations represent lacteal dilation 33 and this could be a primary finding with small cell intestinal lymphoma in dogs or represent concurrent lymphangiectasia that is separate from the lymphoma. The pleural and peritoneal effusion seen in 38% of dogs within the current study was an unexpected finding. The most likely explanation for the effusion found in these dogs is the presence of profound hypoalbuminemia, especially considering that the 3 dogs with sampled effusion was consistent with transudate. However, not all dogs with effusion had an albumin that was considered low enough to explain the presence of effusion. This suggests that other etiologies must be considered for effusion in these dogs, including the potential that it is related to malignancy.
Importantly, study results suggest that an ultrasonographically normal GI tract should not preclude recommendation for intestinal biopsies in dogs with clinical signs of GI disease, as 5 dogs (38%) in the current study did not have any ultrasonographic changes to the GI tract. This has also been reported in 15% of cats with the same disease. 34 Within the current study, the 5 dogs that had an ultrasonographically normal GI tract all either had significant clinical signs attributable to GI disease or hematologic and biochemical abnormalities consistent with GI disease (anaemia, hypoalbuminemia, hypocobalaminemia) which lead to GI biopsies despite the lack of ultrasonographic findings.
Lymphoma was diagnosed in more than 1 region of the intestinal tract in at least 61% of the cases in the current study, which is similar to findings in cats where diffuse or multi-focal disease is common. 17 Given that a majority of dogs in the current study underwent endoscopy for biopsy procurement, it is likely that a higher percentage of dogs had more diffuse or multi-focal disease distribution considering the limitations of endoscopic biopsies, including lack of full-thickness tissue sampling, inability to assess the entirety of the GI tract, especially the ileum which has been proposed as an important site of sampling in cats with intestinal lymphoma. 35 It is possible that dogs with small cell intestinal lymphoma may have been overlooked diagnostically without the addition of ileal biopsies, however overall, 65% of dogs had biopsies from the ileum documented in the current study. Limitations of this study include low case numbers, inconsistent diagnostics and treatments, and its retrospective design which lead to inconsistent follow-up (1 dog in the current study was lost to followup). Survival times may have been underestimated in some, because dogs were considered to be dead of small cell intestinal lymphoma in all cases, and many dogs were humanely euthanized which promotes a more subjective survival analysis. Lastly, as discussed above, the inconsistent method of biopsy procurement is another limitation that may have affected establishment of a diagnosis in some dogs. Future studies with more cases and more uniform treatments will help to better define the clinical features of this disease, and allow for a better understanding of necessities for biopsy procurement.
In conclusion, the results of this study suggest that small cell, T-cell, intestinal lymphoma in dogs is a distinct clinical entity and, if treated, may carry a favourable prognosis. The diagnosis of small cell intestinal lymphoma can be challenging and ultimately requires histopathology with IHC and molecular clonality assessment for definitive confirmation. Further prospective trials will be beneficial to confirm the clinical characteristics and outcome information reported in the current study and to help elucidate the best recommended treatment for these dogs.
